Clinical trial · Observational
The Effects of Preoperative Bevacizumab on Perioperative Complications
The Effects of Preoperative Bevacizumab on Perioperative Complications in Patients With Tumor Undergoing Unexpected Operation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a nationwide multicenter,retrospective,observational real-world study. 1. To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected operation. 2. To assess the correlation of the interval time between the last dose of bevacizumab and operation and occurrence of perioperative complications. 3. To explore the risk factors of perioperative comlications in patients with tumor received bevacizumab prior to unexpected operation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bevacizumab | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Operation Wound; Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Participants with CRC or lung cancer was performed unexpected operation
- description
- This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected operation.
- timeFrame
- 30 days after operation
- description
- To calculate the total incidence of perioperative complications in patients undergoing unexpected surgery after discontinuation of bevacizumab, including wound healing complications, non-wound-related infections, postoperative bleeding, thrombosis, gastrointestinal perforation, anastomotic leakage, secondary surgery, death and other perioperative adverse events;To calculate the incidence of each perioperative complication in patients undergoing unexpected operation after bevacizumab discontinuation.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Patients with colorectal cancer and lung cancer who underwent unexpected operation from 01 Jan 2010 to 31 Dec 2019, and received bevacizumab within 6 weeks (including 6 weeks) before operation; * 2.Patients aged 18-90 years old; * 3.Complete clinical data related to important indicators, including preoperative baseline data, surgical information and perioperative prognosis information. Exclusion Criteria: * Patients who used anti-angiogenic agents other than bevacizumab within 6 weeks prior to unexcepted operation.
References
Publications (0)
Data not yet available